CDR therapeutics and CellGenEx merge to form Xcyte Therapies - Antibody-based products primary focus

被引：0
|
作者：
不详
机构：
来源：
BIOTECHNOLOGY LAW REPORT | 1997年 / 16卷 / 5-6期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：605 / 605
页数：1
相关论文
共 3 条
  • [1] Antibody-based therapeutics: Focus on prostate cancer
    Ross, JS
    Gray, KE
    Webb, IJ
    Gray, GS
    Rolfe, M
    Schenkein, DP
    Nanus, DM
    Millowsky, MI
    Bander, NH
    CANCER AND METASTASIS REVIEWS, 2005, 24 (04) : 521 - 537
  • [2] Antibody-based therapeutics: Focus on prostate cancer
    Jeffrey S. Ross
    Karen E. Gray
    Iain J. Webb
    Gary S. Gray
    Mark Rolfe
    David P. Schenkein
    David M. Nanus
    Mathew I. Millowsky
    Neil H. Bander
    Cancer and Metastasis Reviews, 2005, 24 : 521 - 537
  • [3] The evolution of histone H1 antibodies into cancer therapeutics, part IV: vasopermeation enhancement agents as a case study for histone antibody-based therapies
    Parseghian, Missag H.
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 2006, 84 (04): : 665 - 665
1